Recent progress in nanomedicine: Therapeutic, diagnostic and theranostic applications

Current Opinion in Biotechnology

Volumn 24, Issue 6, 2013, Pages 1159-1166

  Rizzo, Larissa Y ^a   Theek, Benjamin ^a   Storm, Gert ^b,c   Kiessling, Fabian ^a   Lammers, Twan ^a,b,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC APPLICATIONS; DRUG EFFICACY; DRUG-TARGETING; NANOTHERANOSTICS; PHYSIOLOGICAL PROCESS; RECENT PROGRESS; THERAPEUTIC INTERVENTION; THERAPEUTIC PROPERTIES;

DRUG DELIVERY;

MEDICAL NANOTECHNOLOGY;

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CPX 351; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOTA TOC GA 68; DOXORUBICIN; FERUCARBOTRAN; FLUORODEOXYGLUCOSE F 18; GADOMER 17; GOLD NANOPARTICLE; LIPOSOME; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOMATERIAL; POLYMER; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER DIAGNOSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG CANCER; MICROBUBBLE; NANODIAGNOSTIC; NANOMEDICINE; NANOTECHNOLOGY; NANOTHERANOSTIC; NANOTHERAPEUTIC; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SARCOMA; TONSIL TUMOR;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; NANOSTRUCTURES;

EID: 84887621673     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2013.02.020     Document Type: Review

References (52)

1. European Science Foundation's Forward Look Nanomedicine: An EMRC Consensus Opinion (); 2005. http://www.esf.org/.
2. Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanomedicine. N Engl J Med 2010, 363:2434-2443.
3. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101-2141.
4. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3:137-140.
5. Lammers T., Kiessling G., Hennick W.E., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010, 7:1899-1912.
6. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
7. Chen X., Gambhir S.S., Cheon J. Theranostic nanomedicine. Acc Chem Res 2011, 44:841.
8. Lammers T., Aime S., Hennink W.E., Storm G., Kiessling F. Theranostic nanomedicine. Acc Chem Res 2011, 44:1029-1038.
9. Lammers T., Rizzo L.Y., Storm G., Kiessling F. Personalized nanomedicine. Clin Cancer Res 2012, 18:4889-4894.
10. Zhang X.Q., Xu X., Bertrand N., Pridgen E., Swami A., Farokhzad OC Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv Drug Deliv Rev 2012, 64:1363-1384.
11. Mura S., Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012, 64:1394-1416.
12. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J 2005, 19:311-330.
13. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211-1217.
14. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
15. Lammers: Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010, 62:203-230.
16. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
17. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
18. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.
19. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
20. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2012, 10.1016/j.addr.2012.10.002.
21. Liu X.M., Miller S.C., Wang D. Beyond oncology-application of HPMA copolymers in non-cancerous diseases. Adv Drug Deliv Rev 2010, 62:258-271.
22. Lobatto M.E., Fuster V., Fayad Z.A., Mulder W.J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011, 10:835-852.
23. Crielaard B.J., Lammers T., Schiffelers R.M., Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release 2012, 161:225-234.
24. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
25. Choi C.H., Alabi C.A., Webster P., Davis M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010, 107:1235-1240.
26. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007, 104:15549-15554.
27. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009, 6:659-668.
28. Talelli M., Oliveira S., Rijcken C.J., Pieters E.H., Etrych T., Ulbrich K., van Nostrum R.C., Storm G., Hennink W.E., Lammers T. Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 2012, 10.1016/j.biomaterials.2012.09.064.
29. Talelli M., Rijcken C.J.F., Hennink W.E., Lammers T. Polymeric micelles for cancer therapy: 3 C's to enhance efficacy. Curr Opin Solid State Mater Sci 2012, 10.1016/j.cossms.2012.10.003.
30. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
31. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
32. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., Harvie P., Bermudes D., Mayer L. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009, 33:129-139.
33. Feldman E.J., Lancet J.E., Kolitz J.E., Ritchie E.K., Roboz G.J., List A.F., Allen S.L., Asatiani E., Mayer L.D., Swenson C., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011, 29:979-985.
34. Lammers T., Subr V., Peschke P., Kühnlein R., Hennink W.E., Ulbrich K., Kiessling F., Heilmann M., Debus J., Huber P.E., et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 2008, 99:900-910.
35. Lammers T., Subr V., Ulbrich K., Peschke P., Huber P.E., Hennink W.E., Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009, 30:3466-3475.
36. Lammers T., Subr V., Ulbrich K., Hennink W.E., Storm G., Kiessling F. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 2010, 5:197-212.
37. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., Langer R., Farokhzad OC Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 2010, 107:17939-17944.
38. Fink C., Kiesling F., Bock M., Lichy M.P., Misselwitz B., Peschke P., Fusenig N.E., Grobholz R., Delorme S. High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. J Magn Reson Imaging 2003, 18:59-65.
39. Chiribiri A., Kelle S., tze G., Kriatselis S., Thouet C., Tangcharoen T., Paetsch T., Schnackenburg I., Fleck B., Nagel E.E. Visualization of the cardiac venous system using cardiac magnetic resonance. Am J Cardiol 2008, 101:407-412.
40. Wagner S., Schnorr J., Pilgrimm H., Hamm B., Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002, 37:167-177.
41. Politi L.S., Bacigaluppi M., Brambilla E., Cadioli M., Falini A., Comi G., Scotti G., Martino G., Pluchino S. Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells 2007, 25:2583-2592.
42. Reimer P., Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003, 13:1266-1276.
43. Zhu J., Zhou L., XingWu F. Tracking neural stem cells in patients with brain trauma. N Engl J Med 2006, 355:2376-2378.
44. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
45. de Vries I.J., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., Oyen W.J., Bonenkamp J.J., Boezeman J.B., Adema G.J., et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005, 23:1407-1413.
46. Tang T.Y., Howarth S.P., Miller S.R., Graves M.J., Patterson A.J., U-King-Im J.M., Li Z.Y., Walsh S.R., Brown A.P., Kirkpatrick P.J., et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction. of Macrophage Activity) Study. Evaluation using USPIO-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53:2039-2050.
47. Willmann J.K., Paulmurugan R., Chen K., Gheysens O., Rodriguez-Porcel M., Lutz A.M., Chen I.Y., Chen X., Gambhir S.S. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008, 246:508-518.
48. Kiessling F., Fokong S., Koczera P., Lederle W., Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med 2012, 53:345-348.
49. Imhof A., Brunner P., Marincek N., Briel M., Schindler C., Rasch H., Mäcke H.R., Rochlitz C., Müller-Brand J., Walter M.A. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011, 29:2416-2423.
50. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009, 34:1629-1636.
51. Koukourakis M.I., Koukouraki S., Giatromanolaki A., Kakolyris S., Georgoulias V., Velidaki A., Archimandritis S., Karkavitsas N.N. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000, 39:207-211.
52. Soundararajan A., Bao A., Phillips W.T., Perez R., Goins B.A. [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol 2009, 36:515-524.